
    
      In the study, 20 schizophrenic patients are recruited into the 6-week trial and randomly
      assigned into the two groups (1 g/d and 2 g/d) with a double-blind manner. Clinical
      manifestation (Positive and Negative Syndrome Scale; Scale for the Assessment of Negative
      Symptoms), side effects and quality of life are evaluated every two weeks during the trial.
      The efficacies of two groups are compared, and the characteristics of better responders are
      analyzed.
    
  